Clinical Trials
19 trialsNCT02142803 2026-04-29
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT07541781 2026-04-21
Sitagliptin in Recurrent/Progressive Grade 4 Glioma
University of Iowa
Phase 1 Not yet recruiting
NCT02669173 2026-02-23
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02833701 2023-10-24
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT02386826 2023-09-21
INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme
SCRI Development Innovations, LLC
Phase 1 Completed
NCT02285959 2022-08-10
Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme
Global Neurosciences Institute
Phase 1 Unknown
NCT05476341 2022-07-27
A Phase I Clinical Trial of Bevacizumab Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT02010606 2021-11-22
Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1 Completed
NCT03573986 2020-02-17
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT01392209 2019-11-22
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT03631836 2018-08-17
MARELLE01
Assistance Publique Hopitaux De Marseille
Phase 1 Unknown
NCT01526837 2017-07-12
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Brain & Spine Surgeons of New York
Phase 1 Terminated
NCT01308684 2016-11-02
A Dose- and Efficacy-Finding Study of RO5323441 in Combination With Avastin (Bevacizumab) in Patients With Recurrent Glioblastoma
Hoffmann-La Roche
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01435395 2016-04-27
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
Emory University
Phase 1 Completed
NCT00968240 2015-04-22
Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)
Northwell Health
Phase 1 Completed
NCT00762255 2013-07-25
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn